FDA approval is expected at the earliest in 20262027 for CagriSema
This compound is supplied strictly for laboratory research purposes and is not approved for human or veterinary use
BPC-157 is a powerful tool in accelerating recovery, healing tissues, and improving the body's natural regenerative processes
Contraindications Given the limited safety data, conservative contraindications would include pregnancy or plans to become pregnant, breastfeeding, age under 18, severe liver or kidney disease, and any condition requiring medications with unknown interaction potential
Yes, BPC-157 supports the repair of joints, tendons, ligaments, and nerves by promoting tissue regeneration and reducing inflammation
Any use of BPC-157 is considered investigational and should only be discussed with a qualified medical provider